Combination treatment with lapatinib and pazopanib doesn't improve outcomes for patients with IBC
Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting ...
Jun 1, 2012
0
0